Merck Serono and Opexa Therapeutics Enter into Option and License Agreement for Development of Tcelna™ (imilecleucel-T) for Treatment of Multiple Sclerosis
Opexa Therapeutics, 5 Feb 2013
Accessed on 27 Sep 2013 from http://www.opexatherapeutics.com/news-and-resources/press-releases/press-releases-details/2013/Merck-Serono-and-Opexa-Therapeutics-Enter-into-Option-and-License-Agreement-for-Development-of-Tcelna-imilecleucel-T-for-Treatment-of-Multiple-Sclerosis/default.